119673-72-2

Upstream product

• 119673-71-1 Methyl 3S-((t-butyl)diphenylsilyloxy)-4-bromo butanoate 
• 88759-56-2 (S)-bromo-3-hydroxybutyric acid methyl ester 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 119900-72-0 (S)-4--3-<<(1,1-dimethylethyl)diphenylsilyl>oxy>butanoic acid methyl ester 
• 119900-71-9 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-{[(E)-2-(4'-fluoro-3,5,3'-trimethyl-biphenyl-2-yl)-vinyl]-methoxy-phosphinoyl}-butyric acid methyl ester 
• 119900-71-9 (S,Z)-4-[[2-[4'-Fluoro-3,3',5-trimethyl[1,1'-biphenyl]-2-yl]ethenyl]-methoxyphosphinyl]-3-t-butyldiphenyl-silyloxy-butanoic acid, methyl ester 
• 119901-67-6 (S)-4-(hydroxymethoxyphosphinyl)-3-<<(1,1-dimethylethyl)diphenylsilyl>oxy>butanoic acid methyl ester dicyclohexylamine salt 
• 119900-83-3 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-{[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-ylethynyl]-methoxy-phosphinoyl}-butyric acid methyl ester 
• 119900-65-1 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-{[1-(4-fluoro-phenyl)-3-isopropyl-1H-indol-2-ylethynyl]-methoxy-phosphinoyl}-butyric acid methyl ester 
• 119900-84-4 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-({2-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-ethyl}-methoxy-phosphinoyl)-butyric acid methyl ester 
• 119900-66-2 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-({2-[1-(4-fluoro-phenyl)-3-isopropyl-1H-indol-2-yl]-ethyl}-methoxy-phosphinoyl)-butyric acid methyl ester 
• 119900-77-5 (S)-4-[[2-[4'-Fluoro-3,3',5-trimethyl-[1,1'-biphenyl]-2-yl]ethynyl]methoxy-phosphinyl]-3-t-butyldiphenylsilyloxy-butanoic acid, methyl ester 
• 119900-78-6 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-{[2-(4'-fluoro-3,5,3'-trimethyl-biphenyl-2-yl)-ethyl]-methoxy-phosphinoyl}-butyric acid methyl ester 
• 119942-64-2 C₂₇H₄₅O₆PSi₃ 
• 119900-42-4 (S)-4-[[2-[1-(4-Fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl]ethynyl]methoxyphosphinyl]-3-hydroxybutanoic acid, methyl ester 
• 119899-89-7 C₂₅H₃₉O₆PSi₂ 

Relevant academic research and scientific papers

Phosphorus-containing HMG-CoA reductase inhibitors

Novel phosphorus-containing compounds which inhibit the activity of HMG-CoA reductase, including a 5-pyrimidinyl-containing moiety. Pharmaceutical compositions and methods of use for the treatment or prevention of hypercholesterolemia, atheroschlerosis, h

SULFUR-CONTAINING HMG-COA REDUCTASE INHIBITORS

Novel sulfur-containing compounds which inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, having a sulfur-containing side-chain bonded to a hydrophobic anchor group through an acetylenic or ethylenic linkage. Pharmaceutica

Phosphorus-Containing Inhibitors of HMG-CoA Reductase. 2. Synthesis and Biological Activites of a Series of Substituted Pyrydynes Containing a Hydroxyphosphinyl Moiety

A series of 2,3,4,(5),6-substituted pyridines containing a hydroxyphosphinyl functionality have been prepared and were evaluated for their ability to inhibit the enzyme HMG-CoA reductase.Systematic substitution of both R1-R4 and X-Y

HMG-COA REDUCTASE INHIBITORS

Disclosed are novel substituted cyclohexenyl phosphinylhydroxybutyrates as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula: STR1 and pharmaceutically acceptable salts ther